Biofrontera Valuation
Is B8FK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of B8FK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate B8FK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate B8FK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for B8FK?
Key metric: As B8FK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is B8FK's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €21.67m |
| Market Cap | €16.41m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | -5.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does B8FK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13x | ||
SBX SynBiotic | 7.2x | 39.7% | €27.9m |
HIGH Cantourage Group | 29.4x | 38.6% | €57.6m |
APPH Apontis Pharma | 2x | 17.3% | €80.3m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
B8FK Biofrontera | 0.8x | n/a | €16.4m |
Price-To-Sales vs Peers: B8FK is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (13x).
Price to Sales Ratio vs Industry
How does B8FK's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: B8FK is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is B8FK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate B8FK's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.9b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.05
7D
4.9%
1Y
79.5%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$28.60
7D
2.1%
1Y
21.2%